Cresco Labs Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Cresco LabsDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -25.3% zurückgegangen, während in der Branche Pharmaceuticals die Gewinne wachsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 26.6% pro Jahr.

Wichtige Informationen

-25.3%

Wachstumsrate der Gewinne

-13.0%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie	23.1%
Wachstumsrate der Einnahmen	26.6%
Eigenkapitalrendite	-43.2%
Netto-Marge	-23.5%
Letzte Ertragsaktualisierung	30 Jun 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Aug 11

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Jul 17

Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Jun 19

Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 19

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Mar 16

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Mar 03

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

Jan 26

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

Jan 04

Aufschlüsselung der Einnahmen und Ausgaben

Wie Cresco Labs Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

CNSX:CL Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten
30 Jun 24	735	-172	227
31 Mar 24	747	-155	241
31 Dec 23	756	-176	260
30 Sep 23	767	-339	283
30 Jun 23	786	-234	295
31 Mar 23	806	-211	307
31 Dec 22	825	-212	310
30 Sep 22	842	-65	295
30 Jun 22	848	-326	295
31 Mar 22	841	-318	292
31 Dec 21	806	-320	276
30 Sep 21	750	-360	276
30 Jun 21	687	-73	246
31 Mar 21	573	-105	215
31 Dec 20	463	-102	199
30 Sep 20	345	-76	163
30 Jun 20	231	-98	145
31 Mar 20	168	-64	119
31 Dec 19	124	-43	92
30 Sep 19	101	-20	77
30 Jun 19	78	-14	63
31 Mar 19	57	-12	46
31 Dec 18	41	-2	31
30 Sep 18	28	0	19
30 Jun 18	19	1	9
31 Mar 18	13	1	7
31 Dec 17	10	-3	5
31 Dec 16	3	-8	4

Qualität der Erträge: CL ist derzeit unrentabel.

Wachsende Gewinnspanne: CL ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: CL ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 31.3% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von CL verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: CL ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Pharmaceuticals (-19.4%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: CL hat eine negative Eigenkapitalrendite (-43.21%), da es derzeit unrentabel ist.

Cresco Labs Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.12 loss in 2Q 2023)

Cresco Labs Inc. to Report Q2, 2024 Results on Aug 08, 2024

First quarter 2024 earnings released: US$0.015 loss per share (vs US$0.085 loss in 1Q 2023)

Cresco Labs Inc. to Report Q1, 2024 Results on May 15, 2024

Full year 2023 earnings released: US$0.53 loss per share (vs US$0.71 loss in FY 2022)

Cresco Labs Inc. to Report Q4, 2023 Results on Mar 13, 2024

Recent updates

Cresco Labs Inc. Announces CFO Changes

New minor risk - Profitability

No longer forecast to breakeven

Co-Founder & Independent Director recently sold CA$110k worth of stock

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.12 loss in 2Q 2023)

Cresco Labs Inc. to Report Q2, 2024 Results on Aug 08, 2024

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Co-Founder & Independent Director recently sold CA$236k worth of stock

New minor risk - Shareholder dilution

Co-Founder & Independent Director recently sold CA$124k worth of stock

Co-Founder & Independent Director recently sold CA$124k worth of stock

Co-Founder & Independent Director recently sold CA$364k worth of stock

First quarter 2024 earnings released: US$0.015 loss per share (vs US$0.085 loss in 1Q 2023)

Cresco Labs Inc. (CNSX:CL) acquired Two medical dispensaries in Pennsylvania of Keystone Integrated Care, LLC for $9.8 million.

Consensus EPS estimates upgraded to US$0.055 loss

Cresco Labs Inc. to Report Q1, 2024 Results on May 15, 2024

Cresco Labs Inc., Annual General Meeting, Jun 10, 2024

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to US$0.059 loss

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

New minor risk - Profitability

Full year 2023 earnings released: US$0.53 loss per share (vs US$0.71 loss in FY 2022)

Forecast to breakeven in 2025

New minor risk - Shareholder dilution

Chief Financial Officer exercised options to buy CA$150k worth of stock.

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Cresco Labs Inc. to Report Q4, 2023 Results on Mar 13, 2024

Cresco Labs Inc. Promotes Greg Butler to the Position of President

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

New minor risk - Shareholder dilution

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 91%, revenue upgraded

Third quarter 2023 earnings released: US$0.34 loss per share (vs US$0.033 loss in 3Q 2022)

Cresco Labs Inc. to Report Q3, 2023 Results on Nov 15, 2023

New major risk - Share price stability

Cresco Labs Inc. completed the acquisition of Sole Licensed Arizona Operation of Cresco Labs Inc.

No longer forecast to breakeven

Is Cresco Labs (CSE:CL) Using Too Much Debt?

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 42%

Chief Financial Officer recently bought CA$149k worth of stock

Price target decreased by 8.4% to CA$4.80

Cresco Labs Inc. Provides Revenue Guidance for the Second Half of 2023

Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.046 loss in 2Q 2022)

Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 33%

Cresco Labs Inc. to Report Q2, 2023 Results on Aug 16, 2023

Insufficient new directors

Consensus EPS estimates fall by 15%

Price target decreased by 36% to CA$3.82

First quarter 2023 earnings released: US$0.092 loss per share (vs US$0.094 loss in 1Q 2022)

Cresco Labs Inc. to Report Q1, 2023 Results on May 24, 2023

Consensus EPS estimates fall by 40%

Insider recently sold CA$157k worth of stock

Consensus EPS estimates fall by 109%

Full year 2022 earnings released: US$0.71 loss per share (vs US$1.22 loss in FY 2021)

Cresco Labs (CSE:CL) Has A Somewhat Strained Balance Sheet

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 24%?

Now 22% undervalued after recent price drop

Co-Founder & Independent Director recently sold CA$1.7m worth of stock

Forecast breakeven date moved forward to 2023

Forecast breakeven date pushed back to 2024

Now 20% undervalued after recent price drop

Third quarter 2022 earnings released: US$0.011 loss per share (vs US$1.00 loss in 3Q 2021)

Combs Enterprises signed a definitive agreements to acquire Certain New York, Illinois, and Massachusetts assets of Cresco Labs Inc. and Columbia Care Inc. for approximately $190 million.

Price target decreased to CA$10.10